Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
VSCP's Cash to Debt is ranked higher than
92% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. VSCP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
VSCP' s 10-Year Cash to Debt Range
Min: 37.78  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.66
VSCP's Equity to Asset is ranked higher than
50% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. VSCP: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
VSCP' s 10-Year Equity to Asset Range
Min: -0.97  Med: 0.74 Max: 0.88
Current: 0.66
-0.97
0.88
Interest Coverage No Debt
VSCP's Interest Coverage is ranked higher than
89% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. VSCP: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VSCP' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -1.40
M-Score: -1.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -30.50
VSCP's Operating margin (%) is ranked lower than
70% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. VSCP: -30.50 )
Ranked among companies with meaningful Operating margin (%) only.
VSCP' s 10-Year Operating margin (%) Range
Min: -95.59  Med: -28.75 Max: 6.51
Current: -30.5
-95.59
6.51
Net-margin (%) -30.51
VSCP's Net-margin (%) is ranked lower than
70% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. VSCP: -30.51 )
Ranked among companies with meaningful Net-margin (%) only.
VSCP' s 10-Year Net-margin (%) Range
Min: -98.53  Med: -28.66 Max: 4.92
Current: -30.51
-98.53
4.92
ROE (%) -59.07
VSCP's ROE (%) is ranked lower than
81% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. VSCP: -59.07 )
Ranked among companies with meaningful ROE (%) only.
VSCP' s 10-Year ROE (%) Range
Min: -120.47  Med: -35.94 Max: 9.72
Current: -59.07
-120.47
9.72
ROA (%) -38.54
VSCP's ROA (%) is ranked lower than
74% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: -0.33 vs. VSCP: -38.54 )
Ranked among companies with meaningful ROA (%) only.
VSCP' s 10-Year ROA (%) Range
Min: -95.8  Med: -23.25 Max: 6.9
Current: -38.54
-95.8
6.9
ROC (Joel Greenblatt) (%) -949.52
VSCP's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. VSCP: -949.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VSCP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1378.21  Med: -454.87 Max: 202.79
Current: -949.52
-1378.21
202.79
Revenue Growth (3Y)(%) -6.50
VSCP's Revenue Growth (3Y)(%) is ranked lower than
72% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. VSCP: -6.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VSCP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -9.9  Med: 11.90 Max: 573.1
Current: -6.5
-9.9
573.1
» VSCP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

VSCP Guru Trades in Q2 2014

Jim Simons 11,290 sh (New)
» More
Q3 2014

VSCP Guru Trades in Q3 2014

Jim Simons 14,290 sh (+26.57%)
» More
Q4 2014

VSCP Guru Trades in Q4 2014

Jim Simons 15,890 sh (+11.20%)
» More
Q1 2015

VSCP Guru Trades in Q1 2015

Jim Simons 16,090 sh (+1.26%)
» More
» Details

Insider Trades

Latest Guru Trades with VSCP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.63
VSCP's P/B is ranked higher than
77% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. VSCP: 1.63 )
Ranked among companies with meaningful P/B only.
VSCP' s 10-Year P/B Range
Min: 1  Med: 3.85 Max: 19.94
Current: 1.63
1
19.94
P/S 0.64
VSCP's P/S is ranked higher than
89% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. VSCP: 0.64 )
Ranked among companies with meaningful P/S only.
VSCP' s 10-Year P/S Range
Min: 0.64  Med: 2.52 Max: 85.05
Current: 0.64
0.64
85.05
Current Ratio 2.24
VSCP's Current Ratio is ranked lower than
56% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. VSCP: 2.24 )
Ranked among companies with meaningful Current Ratio only.
VSCP' s 10-Year Current Ratio Range
Min: 0.03  Med: 3.17 Max: 6.97
Current: 2.24
0.03
6.97
Quick Ratio 2.24
VSCP's Quick Ratio is ranked higher than
53% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. VSCP: 2.24 )
Ranked among companies with meaningful Quick Ratio only.
VSCP' s 10-Year Quick Ratio Range
Min: 0.03  Med: 3.17 Max: 6.97
Current: 2.24
0.03
6.97
Days Sales Outstanding 70.16
VSCP's Days Sales Outstanding is ranked lower than
52% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 68.45 vs. VSCP: 70.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
VSCP' s 10-Year Days Sales Outstanding Range
Min: 41.88  Med: 52.26 Max: 74.35
Current: 70.16
41.88
74.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 47.00
VSCP's Price/Net Cash is ranked lower than
85% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 14.32 vs. VSCP: 47.00 )
Ranked among companies with meaningful Price/Net Cash only.
VSCP' s 10-Year Price/Net Cash Range
Min: 2.24  Med: 10.00 Max: 242.5
Current: 47
2.24
242.5
Price/Net Current Asset Value 2.53
VSCP's Price/Net Current Asset Value is ranked higher than
89% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 6.26 vs. VSCP: 2.53 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VSCP' s 10-Year Price/Net Current Asset Value Range
Min: 1.35  Med: 5.52 Max: 29.5
Current: 2.53
1.35
29.5
Price/Tangible Book 2.24
VSCP's Price/Tangible Book is ranked higher than
73% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. VSCP: 2.24 )
Ranked among companies with meaningful Price/Tangible Book only.
VSCP' s 10-Year Price/Tangible Book Range
Min: 1.31  Med: 4.59 Max: 23.79
Current: 2.24
1.31
23.79
Price/Median PS Value 0.26
VSCP's Price/Median PS Value is ranked higher than
98% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 1.11 vs. VSCP: 0.26 )
Ranked among companies with meaningful Price/Median PS Value only.
VSCP' s 10-Year Price/Median PS Value Range
Min: 0.32  Med: 0.93 Max: 24.89
Current: 0.26
0.32
24.89
Earnings Yield (Greenblatt) (%) -64.50
VSCP's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. VSCP: -64.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VSCP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 1.40 Max: 3
Current: -64.5
0.1
3

Business Description

Industry: Medical Devices » Medical Devices
Compare:PAYX, AHEXY, RANJY, TMH, HAYPY » details
VirtualScopics Inc. is a provider of quantitative imaging for clinical trials serving the pharmaceutical, biotechnology and medical device industries. The Company has developed a software platform for analysis and modeling of both structural and functional medical images. This platform provides information about the biological activity of drugs and devices in clinical trial patients. VirtualScopics is an imaging core lab providing central reads and quantitative imaging solutions for drug and medical device clinical trials for the areas of oncology, rheumatoid arthritis, osteoarthritis, neurology, and cardiovascular studies utilizing MRI, PET, CT, Ultrasound, and X-ray imaging modalities. The Company's image-based measurement and visualization tools enable automated and reproducible measurement of minute changes that occur in anatomic structures in musculoskeletal, oncological, cardiological and neurological diseases. The Company's image analysis provides a degree of accuracy and reproducibility that cannot be duplicated by manual techniques. The Company's quantitative imaging replaces subjective evaluation. It has developed a suite of patented semi-automated tools for the identification and measurement of carotid plaques. Evaluating diseases such as multiple sclerosis (MS), epilepsy, and Alzheimer's requires the identification and measurement of neurological structures and lesions. The Company's competition is largely comprised of a limited number of university research centers that are working on developing the next generation of image analysis tools. The Company's main customers are Novartis, Merck Serono and Amgen. The Company's main competitors are clinical research organizations (CROs) providing clinical trial services to pharmaceutical companies. Healthcare in the United States is heavily regulated by the federal government, and by state and local governments.
» More Articles for VSCP

Headlines

Articles On GuruFocus.com
VirtualScopics Receives Further Extension to Regain Compliance with Nasdaq Dec 24 2008 

More From Other Websites
VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call... Jul 28 2015
VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call... Jul 28 2015
VirtualScopics and IXICO Alliance Receive Awards in Oncology and Neurodegenerative Disease Jul 10 2015
VirtualScopics and IXICO Alliance Receive Awards in Oncology and Neurodegenerative Disease Jun 29 2015
VirtualScopics Alliance Update Jun 29 2015
Half Yearly Report Jun 29 2015
IXICO and VirtualScopics Alliance Update Jun 29 2015
VIRTUALSCOPICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Jun 05 2015
VirtualScopics, Inc. Reports Voting Results At Annual Meeting Of Shareholders; All Board Seats... Jun 05 2015
VirtualScopics, Inc. Makes Investments In Magnetic Resonance Elastography (MRE) May 27 2015
VIRTUALSCOPICS, INC. Financials May 22 2015
VirtualScopics, Inc. To Webcast Annual Meeting Of Shareholders On June 2, 2015; Five Members Of... May 19 2015
Interim Results May 18 2015
VIRTUALSCOPICS, INC. Files SEC form 10-Q, Quarterly Report May 14 2015
VirtualScopics, Inc. To Present At The 2015 Marcum MicroCap Conference In New York City May 13 2015
VIRTUALSCOPICS, INC. Files SEC form 8-K, Regulation FD Disclosure May 08 2015
VIRTUALSCOPICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... May 06 2015
VirtualScopics, Inc. Reports 2015 First Quarter Financial Results; Revenues Increase 20% From 2014... May 06 2015
VirtualScopics, Inc. to Host First Quarter 2015 Earnings Conference Call and Webcast Live on... May 05 2015
IXICO’s Imaging Data and Query Management Platform, TrialTracker™, operational at VirtualScopics... May 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK